Theranostics 2022; 12(7):3079-3083. doi:10.7150/thno.71788 This issue

Editorial

Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?

Sue-Jane Wang1✉, Anthony Fotenos2, Shane C. Masters2, Louis Marzella2

1. Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
2. Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Wang SJ, Fotenos A, Masters SC, Marzella L. Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?. Theranostics 2022; 12(7):3079-3083. doi:10.7150/thno.71788. Available from https://www.thno.org/v12p3079.htm

File import instruction
Graphic abstract